Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study

Thomas L. Frandsen, Jonas Abrahamsson, Birgitte Lausen, Kim Vettenranta, Mats Heyman, Michael Behrentz, Anders Castor, Peder S. Wehner, Britt‐marie Frost, Elisabeth Wreford Andersen, Kjeld Schmiegelow

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

This study explored the feasibility and toxicity of individualized toxicity‐titrated 6‐mercaptopurine (6MP) dose increments during post‐remission treatment with High‐dose methotrexate (HDM) (5000 mg/m2, ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m2 per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m2 per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity‐titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.
Original languageEnglish
JournalBritish Journal of Haematology
Volume155
Issue number2
Pages (from-to)244-247
ISSN0007-1048
DOIs
Publication statusPublished - 2011
Externally publishedYes

Keywords

  • Acute lymphoblastic leukaemia
  • Chemotherapy
  • Children
  • Consolidation
  • Purine analogues

Fingerprint Dive into the research topics of 'Individualized toxicity‐titrated 6‐mercaptopurine increments during high‐dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia: A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study'. Together they form a unique fingerprint.

Cite this